Clinical trials: Sars-CoV-2 Infection
COVID-19 Vaccine
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above
The purpose of this study is to assess the immunogenicity and safety of MVC- COV1901 vaccine compared to AZD1222 in heathy adults.
- Trial name
- NCT05198596
- Testing
- MVC-COV1901, AZD1222
- Where
- 2 sites in Thailand
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Covid19
Safety, Reactogenicity and Immunogenicity Study of ReCOV
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen that causes a coronavirus-associated acute respiratory disease called coronavirus disease 19 (COVID-19), which is spreading all over the world.
- Trial name
- NCT04818801
- Testing
- Recombinant two-component COVID-19 vaccine (CHO cell)
- Where
- 2 sites in New Zealand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
COVID-19
The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers
Phase 1 randomized, vehicle-controlled, blinded study to assess the safety, tolerability, and PK of single ascending doses of inhaled TLC19 in healthy volunteer subjects.
- Trial name
- NCT04697654
- Testing
- TLC19, TLC19 Vehicle
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Taiwan Liposome Company
COVID-19
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
The scope of this Phase I/II study is to determine whether GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against…
- Trial name
- NCT05602961
- Testing
- GLB-COV2-043, BNT162b2/COMIRNATY®
- Volunteers
- healthy volunteers welcome
- Sponsor
- GreenLight Biosciences, Inc.
Bioequivalence
The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions
A single dose of Reference product containing 200 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride and a single dose of Test product containing 200 mg umifenovir hydrochloride monohydrate…
- Trial name
- Umifenovir (NCT04476719)
- Testing
- ATAFENOVIR 200 MG KAPSUL, ARBIDOL 100 MG KAPSUL
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Atabay Kimya Sanayi Ticaret A.S.
COVID-19
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Increased immune escape of emerging SARS-CoV-2 variants and waning neutralizing antibody levels over time indicate the importance of COVID-19 vaccine booster dose.
- Trial name
- NCT05716347
- Testing
- the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Coronavirus, Covid19
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
The primary objective of this study is to evaluate the humoral immune response to CVnCoV in elderly adults aged ≥65 years and younger adults aged 18-45 years, 14 days after the second dose administration.
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04838847
- Testing
- CVnCoV Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- CureVac
Healthy
To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19
This study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of Niclosamide (DWRX2003) following escalating doses of DWRX2003 administered as an intramuscular injection in healthy volunteers.
- Trial name
- NCT04524052
- Testing
- DWRX2003
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
COVID-19
Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
This is a phase Ⅳ follow-up clinical trial based on the previous Phase Ⅳ clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05329038
- Testing
- Inactivated COVID-19 Vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
COVID-19
Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study
This is a dose exploration study to evaluate the safety and pharmacokinetics (PK) of AZD3152 in healthy adult male and female participants, across different dose levels and routes of administration (ie, Intramuscular [IM]…
- Trial name
- NCT05872958
- Testing
- AZD3152
- Where
- 4 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome
A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.
The COVID-19 pandemic has led to an increase in the number of patients admitted to intensive care units (ICU) with acute respiratory distress syndrome (ARDS).
- Conditions
- Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome, Covid19, ARDS
- Trial name
- IMPRESS COVID (NCT04953052)
- Testing
- Imatinib Mesylate
- Where
- 8 sites in India
- Sponsor
- Exvastat Ltd.
Coronavirus Disease 2019
Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)
Popular topic:Clinical trials of the consistency and non-inferiority bridging between batches of recombinant new coronavirus vaccine (CHO cells) Research purpose:Main purpose:1)To evaluate the interbatch consistency of…
- Trial name
- NCT05091411
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Coronavirus Infection, Covid-19
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine delivered via pMDI compared with a matching placebo in conjunction with standard of care treatments on recovery in patients…
- Conditions
- Coronavirus Infection, Covid-19, SARS-CoV-2
- Trial name
- NCT04527471
- Testing
- Ensifentrine Dose 1
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Verona Pharma Inc
COVID-19
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
Prevention of COVID-19 infection to severe pneumonea or ARDS
- Trial name
- NCT04500132
- Testing
- EC-18
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Enzychem Lifesciences Corporation
COVID-19 Infection
Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection
An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection
- Trial name
- NCT04374032
- Testing
- metenkefalin + tridecactide, The standard of care
- Where
- 5 sites in Bosnia and Herzegovina
- Volunteers
- 120 people
- Sponsor
- Bosnalijek D.D
COVID-19
AZD1222 Vaccine for the Prevention of COVID-19
The purpose of this study is to evaluate safety and immunogenicity of AZD1222 for COVID-19 prevention in the Russian Federation
- Trial name
- NCT04540393
- Testing
- AZD1222
- Where
- 4 sites in Russia
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an injection into a vein.
- Trial name
- BLAZE-5 (NCT04701658)
- Testing
- Bamlanivimab
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198063
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19
This is a randomized, double-blind, placebo-controlled Phase 1 study in participants over the age of 18 years with mild to moderate COVID-19.
- Trial name
- NCT06039163
- Testing
- HH-120
- Where
- 4 sites in China
- Volunteers
- 37 people
- Sponsor
- Huahui Health
Coronavirus Disease 2019 COVID-19
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and…
- Trial name
- NCT04341116
- Testing
- TJ003234
- Where
- 14 sites in United States
- Volunteers
- 149 people
- Sponsor
- I-Mab Biopharma US Limited